---
title: Atrial Fibrillation
author: J. Austin Straley, DO
date: 2024-03-16
categories:
    - Cardiology
    - Electrophysiology
tags:
    - AF
    - Anticoagulation
---
- General[^1]
- Management[^2]
    - AFFIRM[^3]: Rate-control = Rhythm-control; Rate preferred due to Adverse events
    - [RACE-II: Lenient non-inferior to strict rate-control in afib](https://pubmed.ncbi.nlm.nih.gov/20231232/){:target="_blank"}
    - [RAAFT-2: RFA if AAD failed as 1st line for symptomatic PAF](https://pubmed.ncbi.nlm.nih.gov/24549549/){:target="_blank"}
    - [AVERROES: Eliquis > Aspirin alone for Stroke/VTE](https://pubmed.ncbi.nlm.nih.gov/21309657/){:target="_blank"}
    - [ARISTOTLE: Eliquis > Warfarin for stroke, less brain bleeding](https://pubmed.ncbi.nlm.nih.gov/21870978/){:target="_blank"}
    - [ROCKET-AF: Xarelto is non-inferior to Warfarin](https://pubmed.ncbi.nlm.nih.gov/21830957/){:target="_blank"}
    - [BRIDGE: Periprocedural bridging did not reduce ATE, increased bleeding](https://pubmed.ncbi.nlm.nih.gov/26095867/){:target="_blank"}

[^1]: https://www.ncbi.nlm.nih.gov/books/NBK526072/
[^2]: https://pubmed.ncbi.nlm.nih.gov/30144419/
[^3]: https://pubmed.ncbi.nlm.nih.gov/12466506/